ArticleContemporary clinical trials communications2022

Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors.

Maria Carolina Gouveia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.